Documentation of Smoking Complications
Document smoking status as a vital sign at every encounter, including pack-years calculation (cigarettes per day × years smoked ÷ 20), specific complications discussed, counseling provided, and the cessation plan with pharmacotherapy prescribed. 1, 2
Essential Documentation Components
Smoking History Details
- Record the following at every visit: 1, 2
- Current smoking status (never smoker, former smoker, or current smoker—includes anyone who quit within the last 12 months due to high relapse probability) 1
- Cigarettes per day and total years of smoking 1
- Pack-years calculation (daily cigarettes × years ÷ 20) 3, 2
- Type of tobacco products used (cigarettes, cigars, pipes, chewing tobacco, waterpipe/shisha) 1, 3
- Secondhand smoke exposure at home and work 1, 2
- Age at smoking initiation 3, 2
Complications Discussed
Document the specific health risks you counseled the patient about, using quantified data to make the discussion concrete: 1, 3
- Cancer risks: Smoking causes 30% of all cancer deaths and is causally linked to at least 16 cancer types, with 85-90% of lung cancer deaths attributable to cigarette smoking 1, 3
- Cardiovascular risks: The 10-year fatal cardiovascular disease risk is approximately doubled in all smokers regardless of intensity, with no safe threshold for tobacco smoke exposure 3
- Diabetes complications: Smoking 2 packs per day increases diabetes incidence by 45% in men and 74% in women, and exacerbates existing diabetic complications 1
- Surgical outcomes: Document that continued smoking worsens surgical outcomes, though cessation should not delay appropriate timing of cancer resection 1
Readiness to Change Assessment
Document the patient's current stage using the "5 Rs" framework if not ready to quit: 1
If ready to quit, document the "5 As" intervention: 1
- Asked about tobacco use
- Advised to quit in clear, strong, personalized manner
- Assessed willingness to make quit attempt
- Assisted with specific quit plan
- Arranged follow-up 1
Cessation Plan Documentation
Document the specific quit date set (should be within 1-2 weeks) and the complete treatment plan: 1
Pharmacotherapy prescribed: 1, 3
- First-line recommendation: Varenicline 1 mg twice daily for 12 weeks (achieves 21.8% quit rate at 6 months versus 9.4% for placebo) 3, 4
- Alternative first-line: Combination nicotine replacement therapy (patch plus gum/lozenge) with fewer adverse effects than varenicline or bupropion 3
- Second-line option: Bupropion SR 150 mg twice daily 1, 5
- Document contraindications checked and side effects counseled 1, 4, 5
Behavioral counseling plan: 1
- Individual counseling sessions scheduled (weekly for at least 4 weeks) 1
- Problem-solving strategies taught: removal of all tobacco products from home/work before quit date, planning for high-risk situations 1
- Coping skills reviewed: deep breathing for relaxation, changing routines where smoking occurs 1
- Social support identified: partner for quit attempt, addressing other smokers in household 1
Relapse prevention strategies: 1
Follow-Up Plan
- Document specific follow-up schedule: 1
Benefits of Cessation Discussed
Document the timeline of health improvements you reviewed with the patient: 3
- Cardiac death risk decreases by 37% within just 1 year of cessation 3
- Risk of death from coronary heart disease is 50% lower after 1 year of abstinence 3
- Cardiovascular disease risk approaches that of never-smokers within 10-15 years after quitting 3
Critical Documentation Pitfalls to Avoid
- Never document vague statements like "patient counseled on smoking cessation"—specify exactly what complications were discussed and what plan was made 1, 2
- Avoid suggesting e-cigarettes or shisha as "safer" alternatives, as all smoked tobacco is harmful with no safe threshold 3
- Do not delay documentation of smoking status—it should be recorded as a vital sign at every encounter, not just annual visits 2, 6
- Address weight gain concerns proactively in documentation, noting that average weight gain does not diminish the substantial cardiovascular benefit from cessation 3
- Document objective findings when present (e.g., smell of cigarette smoke on patient), but follow up with direct questioning to clarify current use versus secondhand exposure 2
Special Populations
Patients with Psychiatric History
- Document psychiatric comorbidities, as these patients require closer monitoring: 1, 4
- Higher risk of relapse (12.2% clinically significant neuropsychiatric events with varenicline versus 9.5% with placebo in psychiatric cohort) 4
- Consider referral to specialist for management of psychiatric comorbidities 1
- Document that patient was counseled about monitoring for mood changes, agitation, depression, or suicidal thoughts 4, 5